Canadian preference and trends survey results for anti-VEGF treatment of macular edema

Can J Ophthalmol. 2016 Jun;51(3):233-7. doi: 10.1016/j.jcjo.2015.10.014.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Bevacizumab / therapeutic use
  • Canada
  • Diabetic Retinopathy / drug therapy
  • Drug Utilization / trends*
  • Health Care Surveys
  • Humans
  • Macular Edema / drug therapy*
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Ranibizumab / therapeutic use
  • Receptors, Vascular Endothelial Growth Factor / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use
  • Retinal Vein Occlusion / drug therapy
  • Surveys and Questionnaires
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Wet Macular Degeneration / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Recombinant Fusion Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab